Literature DB >> 15915246

Demyelination-like syndrome in Crohn's disease after infliximab therapy.

Hugh J Freeman1, Borys Flak.   

Abstract

An 18-year-old female patient with Crohn's disease involving the ileum and colon developed ankylosing spondylitis. After treatment of her spondylitis with multiple infliximab infusions, new onset of neurological symptoms developed, accompanied by detection of an abnormal white matter signal change on magnetic resonance imaging examination. Although infliximab treatment was terminated, the neurological symptoms and the magnetic resonance imaging changes persisted. Development of new neuropsychiatric changes in Crohn's disease should be thoroughly evaluated to exclude a concomitant demyelinating process. Infliximab infusions should be terminated if demyelination is suspected.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15915246     DOI: 10.1155/2005/358658

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  10 in total

Review 1.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

2.  Neurologic Manifestations of Inflammatory Bowel Disease.

Authors:  Jose M Ferro
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

3.  Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients.

Authors:  K M De Felice; M Novotna; F T Enders; W A Faubion; W J Tremaine; O H Kantarci; L E Raffals
Journal:  Aliment Pharmacol Ther       Date:  2014-10-27       Impact factor: 8.171

4.  Mucinous carcinoma in Crohn's disease originating in a fistulous tract.

Authors:  Hugh J Freeman; Tom Perry; Douglas L Webber; Silvia D Chang; Mong-Yang Loh
Journal:  World J Gastrointest Oncol       Date:  2010-07-15

Review 5.  Neurological adverse events associated with anti-tumor necrosis factor α treatment.

Authors:  Antonio G Tristano
Journal:  J Neurol       Date:  2010-05-22       Impact factor: 4.849

Review 6.  Neurologic manifestations of gastrointestinal and liver diseases.

Authors:  José M Ferro; Sofia Oliveira
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

7.  Central nervous system demyelination associated with etanercept in a 51 years old woman.

Authors:  Wanis H Ibrahim; Mohammed Hammoudah; Naveed Akhtar; Hassan Al-Hail; Dirk Deleu
Journal:  Libyan J Med       Date:  2007-06-01       Impact factor: 1.657

8.  Pathogenic T cell cytokines in multiple sclerosis.

Authors:  Catriona A Wagner; Pamela J Roqué; Joan M Goverman
Journal:  J Exp Med       Date:  2020-01-06       Impact factor: 14.307

9.  Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study.

Authors:  Xiaoying Kang; Alexander Ploner; Nancy L Pedersen; Sara Bandres-Ciga; Alastair J Noyce; Karin Wirdefeldt; Dylan M Williams
Journal:  Neurology       Date:  2021-02-19       Impact factor: 9.910

10.  Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.

Authors:  E Andreadou; E Kemanetzoglou; Ch Brokalaki; M E Evangelopoulos; C Kilidireas; A Rombos; E Stamboulis
Journal:  Case Rep Neurol Med       Date:  2013-05-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.